Safety and Pharmacokinetics of Nicotinamide Mononucleotide (NMN) in Healthy Adults.

NCT ID: NCT04910061 Phase: NA Status: COMPLETED Enrollment: 24 Completion: 2023-03-01

Conditions

Healthy Volunteers

Interventions

Nicotinamide mononucleotide (NMN-C)

Summary

The purpose of this study is to investigate the safety, pharmacokinetic profile, and effects of nicotinamide mononucleotide (NMN-C) in healthy adults, 18-65 years of age. The effects will be studied over the course of 30 days in a repeated-dose study through the collection of blood and urine samples, and administration of surveys and questionnaires.

Primary Outcome

Safety as measured by subject incident of treatment-emergent adverse events

Source

ClinicalTrials.gov